Prosecution Insights
Prosecution Insights
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| §102 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MCKOY, QUINCY ANDRE | 1 | 70.7% | +38.5% |
| CHANG, KYUNG SOOK | 1 | 60.4% | +41.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18565009 | QUINAZOLINE DERIVATIVES USEFUL AS RAS INHIBITORS | MCKOY, QUINCY ANDRE | — |
| 18271913 | PHARMACEUTICAL FORMULATION | CHANG, KYUNG SOOK | — |
| Art Unit | Apps |
|---|---|
| 1626 | 1 |
| 1613 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18565009 | QUINAZOLINE DERIVATIVES USEFUL AS RAS INHIBITORS | MCKOY, QUINCY ANDRE | 1626 | §102 | Non-Final OA | — | Pending | Nov 28, 2023 |
| 18271913 | PHARMACEUTICAL FORMULATION | CHANG, KYUNG SOOK | 1613 | §103 | Final Rejection | — | Pending | Jul 12, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial